Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Advances in Hematology & OncologyMaintenance Therapy With PARP Inhibition in Ovarian Cancer

A Q&A session with Thomas J. Herzog, MD, the Deputy Director at the University of Cincinnati Cancer Center in Ohio, who discusses the PARP inhibitors olaparib (Lynparza, AstraZeneca), niraparib (Zejula, GSK), and rucaparib (Rubraca, Clovis Oncology); the ATHENA-MONO, ENGOT-OV16/NOVA, SOLO2, and ARIEL3 clinical trials; and the implications of the “Dear Health Care Provider” letters that were issued earlier this year regarding PARP inhibitors.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form